Ventyx Biosciences Inc


Prices are adjusted according to historical splits.

Ventyx Biosciences Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$1.99 billion
Book Value:
Revenue TTM:
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Ventyx Biosciences Inc had its IPO on 2021-10-21 under the ticker symbol VTYX.

The company operates in the Healthcare sector and Biotechnology industry. Ventyx Biosciences Inc has a staff strength of 91 employees.

Stock update

Shares of Ventyx Biosciences Inc opened at $34.02 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $34.02 - $35.2, and closed at $34.62.

This is a +1.61% increase from the previous day's closing price.

A total volume of 359,703 shares were traded at the close of the day’s session.

In the last one week, shares of Ventyx Biosciences Inc have increased by +2.58%.

Ventyx Biosciences Inc's Key Ratios

Ventyx Biosciences Inc has a market cap of $1.99 billion, indicating a price to book ratio of 5.015 and a price to sales ratio of 0.

In the last 12-months Ventyx Biosciences Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-169544992. The EBITDA ratio measures Ventyx Biosciences Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Ventyx Biosciences Inc’s operating margin was 0% while its return on assets stood at -34.72% with a return of equity of -55.3%.

In Q2, Ventyx Biosciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Ventyx Biosciences Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-2.86 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ventyx Biosciences Inc’s profitability.

Ventyx Biosciences Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -16.6876. Its price to sales ratio in the trailing 12-months stood at 0.

Ventyx Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$348.76 million
Total Liabilities
$20.03 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Ventyx Biosciences Inc ended 2023 with $348.76 million in total assets and $0 in total liabilities. Its intangible assets were valued at $348.76 million while shareholder equity stood at $327.81 million.

Ventyx Biosciences Inc ended 2023 with $0 in deferred long-term liabilities, $20.03 million in other current liabilities, 6000.00 in common stock, $-318407000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $51.72 million and cash and short-term investments were $332.25 million. The company’s total short-term debt was $439,000 while long-term debt stood at $0.

Ventyx Biosciences Inc’s total current assets stands at $346.70 million while long-term investments were $0.00 and short-term investments were $280.54 million. Its net receivables were $0 compared to accounts payable of $4.09 million and inventory worth $0.

In 2023, Ventyx Biosciences Inc's operating cash flow was $0 while its capital expenditure stood at $195000.

Comparatively, Ventyx Biosciences Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Ventyx Biosciences Inc stock is currently trading at $34.62 per share. It touched a 52-week high of $47.251 and a 52-week low of $47.251. Analysts tracking the stock have a 12-month average target price of $56.75.

Its 50-day moving average was $34.38 and 200-day moving average was $35.24 The short ratio stood at 16.96 indicating a short percent outstanding of 0%.

Around 372.2% of the company’s stock are held by insiders while 10244.7% are held by institutions.

Frequently Asked Questions About Ventyx Biosciences Inc

The stock symbol (also called stock or share ticker) of Ventyx Biosciences Inc is VTYX

The IPO of Ventyx Biosciences Inc took place on 2021-10-21

Similar Industry Stocks (Biotechnology)

Last Price

Most Active

Last Price
Amyris Inc (AMRS)
Humbl Inc (HMBL)

Top Gainers

Last Price
Latch Inc (LTCHW)

Top Losers

Last Price


Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.


662 Encinitas Boulevard, Encinitas, CA, United States, 92024